Max-Planck Institute for Molecular Physiology, Dortmund, Germany
Giliani S.p.A, Milano, Italy
Keywords: IBD, inflammatory bowl diseases, signalling, glucocorticoid receptor
To attract the attention of not only audience at lectures and talks, it is quite common practise to emphasize the importance of studied system by its involvement in diseases. It touches hidden conviction that once the key biological processes are characterised and understood, the development of appropriate drug against the disease is straightforward. Unfortunately, this is not true. How complicated and complex is the road from basic ideas to usable medicament will be demonstrated on the development of drug against inflammatory bowl diseases. At the beginning the aim was clear and target processes – signalling of Rac1 GTPase and glucocorticoid receptors – identified. What followed is the subject of presented work.
1. I. Tiede, G. Fritz, S. Strand, D. Poppe, R. Dvorsky, D. Strand, H.A. Lehr, S. Wirtz, C. Becker, R. Atreya, J. Mudter, K. Hildner, B. Bartsch, M. Holtmann, R. Blumberg, H. Walczak, H. Iven, P.R. Galle, M.R. Ahmadian, M.F. Neurath, J. Clin. Invest. 111, (2003), 1133.
2. M. Löwenberg, A.P. Verhaar, G.R. van den Brink, D.W. Hommes, Trends Mol. Med. 13, (2007), 158.